Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 30
- Registration Number
- NCT00398294
- Locations
- 🇨🇳
Merck Sharp & Dohme (I.A.) Corp., Taipei, Taiwan
Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 355
- Registration Number
- NCT00396175
Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 141
- Registration Number
- NCT00395473
Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)
Phase 3
Terminated
- Conditions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 550
- Registration Number
- NCT00395603
Linear Growth Study (0476-097)(COMPLETED)
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 360
- Registration Number
- NCT00395408
Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 566
- Registration Number
- NCT00394355
Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 12
- Registration Number
- NCT00394160
PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 14
- Registration Number
- NCT00394069
Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 319
- Registration Number
- NCT00393211
Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 325
- Registration Number
- NCT00393354
© Copyright 2024. All Rights Reserved by MedPath